Apple is exploring the development of brain-computer interfaces (BCIs) that could enable users, particularly those with mobility issues, to control their iPhones, iPads, and Vision Pro headsets using neural signals. According to the Wall Street Journal, Apple is collaborating with Synchron, a privately held company based in New York City and backed by prominent investors such as Jeff Bezos and Bill Gates. This partnership marks a significant step in the growing BCI industry, which is expected to expand considerably over the next few decades. Elon Musk's Neuralink is currently a leading player in this field, having successfully implanted its devices in three individuals by January. However, Synchron's approach differs significantly from Neuralink's. Instead of embedding the N1 implant directly into the brain, Synchron's Stentrode—a stent-like device—is placed on the surface of the brain. This method avoids the invasive surgery required by Neuralink, making it a less risky option for potential users. The Stentrode functions by reading brain signals with its electrodes and translating them into actions like on-screen navigation and icon selection. Synchron's device is compatible with switch control, an existing accessibility feature in Apple's operating system. Switch control allows users to operate their devices with external adaptive tools, such as joysticks or switches. Now, the Stentrode can be used as an additional input method, further enhancing accessibility for people with severe physical impairments. Since 2019, Synchron has implanted the Stentrode in 10 individuals, including Mark Jackson, a Pittsburgh resident diagnosed with ALS. The Wall Street Journal recently profiled Jackson, who has been testing the Stentrode with the Apple Vision Pro headset. While wearing the headset, he experienced a virtual visit to Switzerland, complete with panoramic views and sensory feedback. Despite these advancements, Jackson noted that the Stentrode's navigation is significantly slower compared to traditional input methods like mice or touchscreens. This is partly because the Stentrode captures fewer brain signals than Neuralink's N1 device, which is equipped with many more electrodes. As a result, the process of translating brain signals into specific commands is more complex and time-consuming. These developments in BCI technology are part of a broader effort to secure full FDA approval for such implants, which is anticipated but not expected to materialize for several more years. Dr. Tom Oxley, the CEO and co-founder of Synchron, praised Apple for its role in advancing BCI integration. "Apple is helping to pioneer a new interface paradigm, where brain signals are formally recognized alongside touch, voice, and typing," he said. "With BCIs recognized as a native input for Apple devices, there are new possibilities for people living with paralysis and beyond." The collaboration between Apple and Synchron highlights a promising future for BCIs, where they could become a standard input method, significantly improving the lives of individuals with limited mobility. As the technology matures and regulatory hurdles are overcome, it holds the potential to revolutionize how we interact with digital devices, offering greater independence and connectivity to millions of people worldwide.